Betta Pharmaceuticals Co., Ltd. (SHE:300558)
64.44
+6.56 (11.33%)
Jun 29, 2026, 3:04 PM CST
Betta Pharmaceuticals Revenue
Betta Pharmaceuticals had revenue of 1.04B CNY in the quarter ending March 31, 2026, with 13.33% growth. This brings the company's revenue in the last twelve months to 3.73B, up 21.40% year-over-year. In the year 2025, Betta Pharmaceuticals had annual revenue of 3.61B with 24.81% growth.
Revenue (ttm)
3.73B
Revenue Growth
+21.40%
P/S Ratio
7.27
Revenue / Employee
2.09M
Employees
1,785
Market Cap
27.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.61B | 717.39M | 24.81% |
| Dec 31, 2024 | 2.89B | 435.75M | 17.74% |
| Dec 31, 2023 | 2.46B | 79.57M | 3.35% |
| Dec 31, 2022 | 2.38B | 130.77M | 5.82% |
| Jan 1, 2022 | 2.25B | 375.59M | 20.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Humanwell Healthcare (Group) | 23.93B |
| Livzon Pharmaceutical Group | 11.71B |
| Changchun High-Tech Industry (Group) | 11.67B |
| Zhejiang Huahai Pharmaceutical | 8.55B |
| Tasly Pharmaceutical Group | 8.35B |
| Shijiazhuang Yiling Pharmaceutical | 7.91B |
| Dong-E-E-Jiao | 6.80B |
| Hubei Jumpcan Pharmaceutical | 5.90B |
Betta Pharmaceuticals News
- 9 months ago - Chinese healthcare, biotech firms flock to Hong Kong for IPOs - South China Morning Post